Lymphoid-specific tyrosine phosphatase (LYP) inhibitors
The present disclosure relates to novel lymphoid-specific tyrosine phosphatase (LYP, encoded by the PTPN22 gene) inhibitors, and to methods of making and using the novel LYP inhibitors. Thus, the compounds according to the disclosure may be used for treating diseases or disorders associated with PTPN22 genetic polymorphism, including type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosis, Graves' disease, Addison's disease, vitiligo, juvenile arthritis, Hashimoto thyroiditis, and other rarer diseases. Furthermore, these LYP inhibitors may be served for a novel class of cancer immunotherapy. The compounds can be injected or orally administered.
1. A compound of formula I:
or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:
R 1 and R 2 independently represents a group selected from hydrogen, optionally substituted (C 1 -C 4 ) alkyl, optionally substituted (C 4 -C 8 ) cycloalkyl, optionally substituted (C 2 -C 4 ) alkylcarbonyl, optionally substituted (C 4 -C 8 ) cycloalkylcarbonyl, optionally substituted aryl, optionally substituted arylcarbonyl, optionally substituted heterocyclyl, wherein the heterocyclyl ring is 5-7 membered ring containing 1 to 4 heteroatoms selected from O, S, and N, optionally substituted heterocyclycarbonyl, optionally substituted (C 1 -C 4 ) alkyl-SO 2 -, optionally substituted aryl-SO 2 -;
wherein the said groups are substituted by hydrogen, halogen, hydroxy, amino, nitro, CF 3 , cyano, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, or (C 1 -C 4 ) alkyl-amino;
R 3 represents a group selected from H, optionally substituted (C 1 -C 4 ) alkyl, optionally substituted (C 1 -C 4 ) alkenyl, optionally substituted (C 1 -C 4 ) alkynyl, optionally substituted (C 4 -C 8 ) cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl, wherein the heteroaryl and heterocyclyl are 5-7 membered rings with 0-3 sites of unsaturation containing 1 to 4 heteroatoms selected from O, S, and N and, wherein the said groups are substituted by hydrogen, halogen, hydroxy, amino, nitro, CF 3 , cyano, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or C 1 -C 4 alkyl-amino;
R 4 and R 6 independently represents a group selected from hydrogen, optionally substituted (C 1 -C 4 ) alkyl, optionally substituted (C 4 -C 8 ) cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl, wherein the heteroaryl is 5-7 membered ring containing 1 to 4 heteroatoms selected from O, S, and N and, wherein the said groups are substituted by hydrogen, halogen, hydroxy, amino, nitro, CF 3 , cyano, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or C 1 -C 4 alkyl-amino;
(R 5 )n represents a group selected from —H, —F, —Cl, —Br, —I, —CFH 2 , —CF 2 H, —CF 3 , —CN, —OH, —NO 2 , —NH 2 , —SO 2 CH 3 , SO 2 NH 2 , —SO 2 NHCH 3 , —CO 2 -(C 1 -C 4 ) alkyl, NH(C 1 -C 4 ) (alkyl) or N(C 1 -C 4 )(alkyl) 2 , (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkenyl, (C 1 -C 4 ) alkoxy, (C 4 -C 8 ) cycloalkyl; wherein n is 1 or 2;
X is O or H, wherein —C═X— is —CH 2 —when X is H; and
Y is C—R 5 or N, wherein R 5 is as defined above.
2. The compound of claim 1 , wherein R 4 and R 6 are H, and R 3 is C 1 -C 4 alkyl.
3. The compound of claim 1 , wherein at least one of R 1 and R 2 is H.
4. The compound of claim 1 , wherein R 4 and R 6 are H, R 3 is C 1 -C 4 alkyl, and at least one of R 1 and R 2 is H.
5. The compound of claim 1 , wherein one of R 1 and R 2 is an optionally substituted biphenylcarbonyl or optionally substituted phenylcarbonyl, wherein the biphenylcarbonyl or phenylcarbonyl are substituted by hydrogen, halo, hydroxy, amino, nitro, CF 3 , cyano, C 1 - C 4 alkyl, C 1 -C 4 alkoxy or C 1 -C 4 alkyl-amino.
6. The compound of claim 1 , wherein X is O.
7. The compound of claim 1 , wherein Y is —C—H, C—F, C—Cl, C—Br, C—I, Or N.
8. The compound of claim 1 , wherein the compound is selected from the group consisting of:
and any stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
9. A method of treating a patient in need of cancer immunotherapy for colon cancer which method comprises administering to the patient a therapeutically effective amount of the compound of claim 1 , or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof.
10. The method of claim 9 , wherein the therapeutically effective amount is administered orally or intravenously.